Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
CA-125 in population screening and personalized monitoring
https://doi.org/10.33667/2078-5631-2024-4-17-21
Abstract
The increased level of CA-125 in the vast majority of cases is associated with the pathological process of both oncological and non-oncological etiology. Encouraging data on the clinical informativeness of CA-125 and the simplicity of its laboratory determination are the reason for a long-term discussion about the use of this marker not only for assessing the dynamics of ovarian cancer, but also in population screening, as well as in personalized monitoring of women’s health. The article substantiates the inclusion of CA-125 in algorithms for personalized monitoring of women’s health and modern aspects of post-analytical evaluation of test results: assessment of measurement uncertainty, identification of reliable dynamics between successive results and the use of multiple boundaries of clinical decision. The form of a detailed report on the performed laboratory study is proposed.
About the Authors
N. A. Kovyazina
Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation
Russian Federation
Kovyazina Nadezhda A., DM Sci (habil.), head of the Laboratory of Serological Research and Allergy Diagnostics of Dept of Laboratory Diagnostics
Saint-Petersburg
N. A. Alkhutova
Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation
Russian Federation
Alkhutova Natalya A., PhD Bio Sci, senior researcher at the Research Dept of Laboratory Diagnostics of the Research Center
Saint-Petersburg
O. L. Zhizhuna
Saint Petersburg State University
Russian Federation
Russian Federation
Zhizhina Olga L., PhD Med, associate professor at Dept of Propaedeutics of Internal Diseases
Saint-Petersburg
S. S. Aleksanin
Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation
Russian Federation
Aleksanin Sergey S., DM Sci (habil.), professor, Corresponding Member of the Russian Academy of Sciences, director
Saint-Petersburg
References
1. Sources of variation and establishment of Russian reference intervals for major hormones and tumor markers / A. Ruzhanskaya, K. Ichihara, S. Evgina, I. Skibo, N. Vybornova, A. Vasiliev, G. Agarkova, V. Emanuel // PLoS One. 2021. – Vol. 16. – No. 1. – P. e0234284. DOI: 10.1371/journal.pone.0234284.
2. Onkologiya: Nacional’noe rukovodstvo. Kratkoe izdanie. V. I. Chissov, M. I. Davydov (ed.). Moscow: GEOTAR-Media, 2017. 576 p. ISBN 978–5–9704–3982–1. (In Russ.)
3. Tuxen, M. K. Tumor marker CA125 in ovarian cancer / M. K. Tuxen // Journal of Tumor Marker Oncology. 2001. – Vol. 16. – No. 1. – P. 49–67.
4. Behnamfar, F. Are ROMA and HE 4 more accurate than CA-125, in predicting of ovarian epithelial carcinoma? / F. Behnamfar, A. Zafarbakhsh, N. Ahmadian // Advanced Biomedical Research. 2023. – 2:156. DOI: 10.4103/abr.abr_264_22.
5. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. The International Journal of Gynecological Cancer / G. Sölétormos, M. J. Duffy, Abu Hassan S. Othman, R. H. Verheijen, B. Tholander, R. C. Jr. Bast, K. N. Gaarenstroom, C. M. Sturgeon, J. M. Bonfrer, P. H. Petersen, H. Troonen, G. Carlo-Torre, J. Kanty Kulpa, M. K. Tuxen, R. Molina. 2016. – Vol. 26. – No. 1. – P. 43–51. DOI: 10.1097/IGC.0000000000000586.
6. Clinical significance of biomarkers in ovarian cancer, prostate cancer, colorectal cancer / N. V. Marshutina, M. P. Solokhina, I. I. Alentov, N. S. Sergeeva // Research and Practical Medicine Journal. 2016. – Vol. 3. – No. 1. – P. 46–57. (In Russ.)
7. Stewart, C. Ovarian Cancer: An Integrated Review / C. Stewart, C. Ralyea, S. Lockwood // Seminars Oncology Nursing. 2019. – Vol. 35. – No. 2. – P. 151–156. DOI: 10.1016/j.soncn.2019.02.001.
8. Marshutina, N. V. Opuholeassociirovannye markery v skriningovyh programmah, napravlennyh na aktivnoe vyyavlenie raka yaichnikov: real’nost’, problemy i perspektivy / N. V. Marshutina, N. S. Sergeeva // Practical oncology. 2010. – Vol. 11. – No. 2. – P. 109–118. (In Russ.)
9. Esmo Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of ovarian cancer / Esmo Guidelines Task Force // Annals of Oncology. 2001. – Vol. 12. – No. 9. – P. 1205–1207.
10. Montagnana, M. Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective / M. Montagnana, M. Benati, E. Danese // The Annals of Translational Medicine. 2017. – Vol. 5. – No. 13. – P. 276.
11. Prospects of early diagnosis of ovarian cancer / L. Ashrafian, I. Antonova, O. Aleshikova, N. Babayeva, S. Ivashina, A. Liustik, E. Gerfanova // Vestnik Rossijskogo nauchnogo centra rentgenoradiologii Minzdrava Rossii. URL: http://vestnik.rncrr.ru/vestnik/v14/papers/aleshikova_v14.pdf (In Russ.)
12. HE 4 in ovarian cancer: from discovery to clinical application / M. Montagnana, E. Danese, S. Giudici, M. Franchi, G. C. Guidi, M. Plebani, G. Lippi // Advances in Clinical Chemistry. 2011. – Vol. 55. – P. 1–20.
13. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer / G. D. Aletti, S. C. Dowdy, K. C. Podratz, W. A. Cliby // American Journal of Obstetrics and Gynecology. 2007. – Vol. 197. – No. 6. – P. 676.e1–7.
14. Tumour markers in gynaecological cancers – EGTM recommendations. European Group on Tumor Markers. Anticancer Research / O. Segurado, J. Вonfrer, М. J. Duffy [et al.] 1999. – Vol. – No. 4. – P. 2807–1280.
15. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish “MALOVA” Ovarian Cancer Study / E. V. Høgdall, L. Christensen, S. K. Kjaer [et al.] // Gynecologic Oncology. 2007. – Vol. 104. – No. 3. – P. 508–515.
16. Advances in diagnosis and management of ovarian cancer. S. A. Farghaly (ed.). New York: 2014. P. 33–58. ISBN: 978–1–4614–8270–3
17. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers / C. M. Sturgeon, M. J. Duffy, U. H. Stenman [et al.] // Clinical Chemistry. 2008. – Vol. 54. – No. 12. – P. e11–79.
18. Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) / W. Stott, A. Gentry-Maharaj, A. Ryan, N. Amso, M. Seif, C. Jones, I. Jacobs, M. Parmar, U. Menon, S. Campbell, M. Burnell. F1000Res. 2018. – No. 7. – 1241p.
19. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening / U. Menon, A. Ryan, J. Kals [et al.] // Journal of Clinical Oncology. 2015. – Vol. 33. – No. 18. – P. 2062–2071.
20. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial / I. J. Jacobs, U. Menon, A. Ryan [et al.] // Lancet. 2016. – Vol. 387. – P. 945–956.
21. The cost-effectiveness of screening for ovarian cancer: Results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) / U. Menon, A. J. McGuire, M. Raikou [et al.] // British Journal of Cancer. 2017. – Vol. 117. – No. 5. – P. 619–627.
22. Husseinzadeh, N. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review / N. Husseinzadeh // Gynecologic Oncology. 2011. – Vol. 120. – No. 1. – P. 152–157.
23. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? / L. J. Havrilesky G. D., Sanders, S. Kulasingam, E. Myers R. // Gynecologic Oncology. 2008. – Vol. 111. – № 2. – P. 179–87. DOI: 10.1016/j.ygyno.2008.07.006.
24. Kaprin Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer / N. S. Sergeeva, T. E. Skachkova, N. V. Marshutina, B. Ia. Alekseev, A. D. // P. A. Herzen Journal of Oncology. 2018. – No. 1. – P. 55–67. (In Russ.)
25. Semenov, N. N. Elevated levels of CA125 (MUC 16) in metastatic gastric cancer as a strong predictor of poor survival / N. N. Semenov, K. Dalgatov //Malignant tumours. 2022. – Vol. 12. – No. 1. – P. 44–50. DOI: 10.18027/2224–5057–2022–12–1–44–50. (In Russ.)
26. CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19–9 or CA242 / K. Björkman, H. Mustonen, T. Kaprio, H. Kekki, K. Pettersson, C. Haglund, C. Böckelman // Tumour Biology. 2021. – Vol. 43- No. 1. – P. 57–70. DOI: 10.3233/TUB-200069.
27. CA-125 variation in acute heart failure: a single-centre analysis / Patrícia Lourenço, Filipe M. Cunha, Catarina Elias, Catarina Fernandes, Isaac Barroso, João T. Guimarães, Paulo Bettencourt // ESC Heart Failure. 2022. – № 9. – P. 1018–1026. DOI: 10.1002/ehf2.13758
28. Evaluation of serum and salivary ca-125 in breast cancer patients – an analytical study / Urvashee Dwivedi, Anurag Jain, Fatima Bhopalwala Ali, Mustafa Ali // Asian Journal of Pharmaceutics. 2023. – Vol. 16. – No. 4. – P. 97–99.
29. Serum Markers CA125, CA153, and CEA along with Inflammatory Cytokines in the Early Detection of Lung Cancer in High-Risk Populations / G. Li, H. Zhang, L. Zhang, H. Liu, S. Li, Y. Wang, X. Deng // BioMed Research International. 2022. Article ID 1394042. – 4 p. DOI: 10.1155/2022/1394042.
30. Measurement uncertainty estimation technology: justification and experience of implementation in medical practice / N. A. Kovyazina, N. A. Alhutova, A. G. Chunovkina, V. L. Emanuel // Medical alphabet. 2022. – No. 19 – P. 7–11. DOI: 10.33667/2078–5631–2022–19–7–11
31. Kovyazina, N. A. Biological variation – contribution to clinical uncertainty and the role in quality ensuring of quantitative laboratory studies / N. A. Kovyazina, N. A. Alhutova, S. S. Aleksanin // Quality management in medicine. 2023. No. 3. P. 101–107. (In Russ.)
32. MI 3664–2022: Recommendation of the State System for ensuring the Uniformity of Measurements ‘Medical laboratories. Estimation of measurement uncertainty in quantitative immunochemiluminescence analysis. Practical guide’. 2022. (In Russ.)
Review
For citations:
Kovyazina N.A., Alkhutova N.A., Zhizhuna O.L., Aleksanin S.S. CA-125 in population screening and personalized monitoring. Medical alphabet. 2024;(4):17-21. (In Russ.) https://doi.org/10.33667/2078-5631-2024-4-17-21
Views:
62
Email this article 